Last reviewed · How we verify
Cingal
Cingal is a Small molecule drug developed by Anika Therapeutics, Inc.. It is currently in Phase 3 development. Also known as: HA + TH.
Cingal is a treatment that combines hyaluronic acid with triamcinolone hexacetonide, used to study conditions such as knee osteoarthritis and anterior knee pain syndrome. It has been studied in clinical trials as a single injection treatment for these conditions.
-
Baseline phase 3 → approval rate
+58.3pp
Industry-wide phase 3 drugs reach approval ~58.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).
| Regulator | Country | Likely year | Lag vs FDA |
|---|---|---|---|
| FDA | US | 2028–2030 | — |
| EMA | EU | 2029–2031 | +0.7 yr |
| MHRA | GB | 2029–2031 | +0.7 yr |
| Health Canada | CA | 2029–2032 | +0.9 yr |
| TGA | AU | 2029–2032 | +1.2 yr |
| PMDA | JP | 2029–2032 | +1.5 yr |
| NMPA | CN | 2030–2033 | +2.3 yr |
| MFDS | KR | 2029–2032 | +1.4 yr |
| CDSCO | IN | 2029–2033 | +1.8 yr |
| ANVISA | BR | 2030–2033 | +2.3 yr |
Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).
Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.
At a glance
| Generic name | Cingal |
|---|---|
| Also known as | HA + TH |
| Sponsor | Anika Therapeutics, Inc. |
| Modality | Small molecule |
| Therapeutic area | Other |
| Phase | Phase 3 |
Approved indications
Common side effects
- Headache
- Arthralgia
- Viral upper respiratory tract infection
- Injection site pain
- Joint swelling
- Toothache
- Bronchitis
- Upper respiratory tract infection
- Urinary tract infection
- Back pain
- Spinal pain
- Joint injury
Key clinical trials
- Effectiveness of Cingal™ for Improving Pain Scores and Function in Anterior Knee Pain (NA)
- Study of Cingal® for Symptomatic Relief of Osteoarthritis of Ankle Joint (NA)
- Study of Cingal® for Symptomatic Relief of Osteoarthritis of Hip Joint (NA)
- Study of Cingal® for Symptomatic Relief of Osteoarthritis of Shoulder Joint (NA)
- Comparison of the Analgesic Effect of 2 Shoulder Infiltrations (NA)
- A Prospective Evaluation of the Cingal Injection for Hip Osteoarthritis (NA)
- Study of Cingal® and Triamcinolone Hexacetonide for the Relief of Knee Osteoarthritis Pain (PHASE3)
- Cingal Study for Knee Osteoarthritis (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Cingal CI brief — competitive landscape report
- Cingal updates RSS · CI watch RSS
- Anika Therapeutics, Inc. portfolio CI
Frequently asked questions about Cingal
What is Cingal?
Who makes Cingal?
Is Cingal also known as anything else?
What development phase is Cingal in?
What are the side effects of Cingal?
Related
- Manufacturer: Anika Therapeutics, Inc. — full pipeline
- Therapeutic area: All drugs in Other
- Also known as: HA + TH
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing